NCI Cancer Therapy Evaluation Program

NCI Cancer Therapy Evaluation Program
Name	NCI Cancer Therapy Evaluation Program
Formation	1955
Headquarters	Bethesda, Maryland
Parent organization	National Cancer Institute

NCI Cancer Therapy Evaluation Program is a program within the National Cancer Institute responsible for coordinating clinical development, evaluation, and regulatory translation of cancer therapeutics and devices. The program interfaces with academic centers, pharmaceutical companies, biotechnology firms, regulatory agencies, and cooperative groups to design and execute oncology trials and expedite interventions from laboratory discovery to patient care. Its activities intersect with multiple federal initiatives, academic consortia, and industry partnerships that shape contemporary oncologic research and treatment standards.

History

The program traces roots to post‑World War II biomedical expansions tied to the National Institutes of Health and early chemotherapeutic trials at institutions such as Memorial Sloan Kettering Cancer Center, Mayo Clinic, and Johns Hopkins Hospital. Through the 1960s and 1970s it evolved alongside landmark efforts like the National Cancer Act of 1971 and coordinated responses involving Food and Drug Administration, American Cancer Society, and cooperative groups including the Cancer and Leukemia Group B and Southwest Oncology Group. In the 1990s and 2000s the program adapted to molecular oncology advances exemplified by projects at Dana‑Farber Cancer Institute, Fred Hutchinson Cancer Center, and collaborations with biotechnology firms such as Genentech and Amgen. Recent decades have seen alignment with initiatives from the Precision Medicine Initiative and partnerships with networks like the NCI Community Oncology Research Program and the Clinical Trials Transformation Initiative.

Mission and Organization

The program's mission aligns with the National Cancer Institute charter, focusing on clinical evaluation, trial oversight, and translational development across therapeutic modalities including small molecules, biologics, immunotherapies, and devices. Organizationally it liaises with offices such as the Center for Cancer Research, the Division of Cancer Treatment and Diagnosis, and the Office of Cancer Clinical Proteomics Research, while interacting with external bodies like the American Society of Clinical Oncology, European Medicines Agency, and academic consortia at University of California, San Francisco and University of Texas MD Anderson Cancer Center. Leadership typically coordinates with officials from the Department of Health and Human Services, principal investigators at cooperative groups, regulatory liaisons at the Food and Drug Administration, and funding partners including the Bill & Melinda Gates Foundation in specific collaborative programs.

Clinical Trial Phases and Programs

The program manages portfolios spanning early‑phase to late‑phase clinical trials, including phase I dose‑finding studies, phase II efficacy assessments, and phase III randomized comparisons often run through cooperative groups like Eastern Cooperative Oncology Group and Children's Oncology Group. Specialized programs address rare tumors and pediatric oncology involving partners such as St. Jude Children's Research Hospital and initiatives modeled on the Cancer Moonshot. It administers master protocol designs used in adaptive trials, umbrella trials, and basket trials, methods championed by investigators at Memorial Sloan Kettering Cancer Center and exemplified in consortia with Broad Institute scientists. The program supports translational endpoints by coordinating with laboratories at Cold Spring Harbor Laboratory and bioinformatics groups at Stanford University and Harvard Medical School.

Drug and Device Review Processes

Drug and device review processes are structured to align with regulatory frameworks from the Food and Drug Administration, incorporating investigational new drug applications, investigational device exemptions, and expedited pathways such as breakthrough therapy designation and priority review mechanisms used in approvals involving firms like Pfizer, Bristol‑Myers Squibb, and AstraZeneca. Preclinical evaluation often involves collaborations with researchers at National Institutes of Health intramural labs and toxicology studies run with specialized centers at Wake Forest Baptist Medical Center. Pharmacokinetic and pharmacodynamic assessments draw on clinical pharmacology expertise from Mayo Clinic and Cleveland Clinic, while real‑world evidence and post‑market surveillance engage registries maintained by organizations such as SEER Program and networks affiliated with American College of Surgeons.

Partnerships and Collaborations

Partnerships span academia, industry, foundations, and international agencies: joint ventures with Genentech, consortia with Novartis, cooperative agreements with EORTC, and programmatic links to philanthropic funders like Susan G. Komen and Lustgarten Foundation. Multisector initiatives bring together investigators from Johns Hopkins University, software and data partners including Google health computing groups, and international research bodies such as the World Health Organization and European Organisation for Research and Treatment of Cancer. The program also engages patient advocacy groups including American Lung Association and Leukemia & Lymphoma Society, and participates in global consortia addressing access and capacity building with stakeholders like PATH.

Impact and Notable Contributions

The program has contributed to the development and evaluation of numerous oncology standards of care, supporting trials that led to approvals of agents from companies such as Merck (immune checkpoint inhibitors), Roche (targeted therapies), and Celgene (hematologic agents). Its trial infrastructure has enabled landmark studies at Dana‑Farber Cancer Institute, practice‑changing results disseminated through venues like the American Society of Clinical Oncology annual meeting, and translational advances reported in journals associated with Nature Publishing Group and The New England Journal of Medicine. Contributions include facilitation of precision oncology trials linked to genomic profiling initiatives at Broad Institute and policy influence through coordination with the Food and Drug Administration and legislative stakeholders tied to the 21st Century Cures Act.

Category:Cancer research organizations Category:National Cancer Institute